Brentjens, Renier Joseph

Publications

Sort by

Co-Author Network

selected publications

Author Correction: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. 2024 GET IT
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nature medicine. 2023 Academic Article GET IT
IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. The Journal of clinical investigation. 2023 Academic Article GET IT
Times cited: 17
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine. 2023 Academic Article GET IT
MEETING HIGHLIGHTS: THE THIRD MARIE SKŁODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2023. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2023 Academic Article GET IT
GPRC5D-Targeted CAR T Cells for Myeloma. Reply. The New England journal of medicine. 2022 Letter GET IT
CAR T cell therapy: looking back and looking forward. Nature cancer. 2022 Academic Article GET IT
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. 2022 GET IT
GPRC5D-Targeted CAR T Cells for Myeloma. The New England journal of medicine. 2022 Academic Article GET IT
Times cited: 107
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature reviews. Clinical oncology. 2022 Review GET IT
Times cited: 63
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature medicine. 2022 Academic Article GET IT
Times cited: 115
Multipurposing CARs: Same engine, different vehicles. Molecular therapy : the journal of the American Society of Gene Therapy. 2022 Review GET IT
Times cited: 8
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 24
Engineering CAR-T cells to activate small-molecule drugs in situ. Nature chemical biology. 2021 Academic Article GET IT
Human cytomegalovirus expands a CD8⁺ T cell population with loss of BCL11B expression and gain of NK cell identity. Science immunology. 2021 Academic Article GET IT
Times cited: 20
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood advances. 2021 Academic Article GET IT
Times cited: 65
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021 Academic Article GET IT
Times cited: 38
Depletion of high-content CD14⁺ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. Molecular therapy. Methods & clinical development. 2021 Academic Article GET IT
Times cited: 12
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. Frontiers in immunology. 2021 Academic Article GET IT
Times cited: 22
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021 Academic Article GET IT
Times cited: 20
Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future. Cancer journal (Sudbury, Mass.). 2021 Editorial Article GET IT
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15^th-16^th February 2019, Doha, Qatar. Frontiers in immunology. 2021 Conference Paper GET IT
Times cited: 1
Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nature communications. 2020 Academic Article GET IT
Times cited: 74
CD103⁺ cDC1 and endogenous CD8⁺ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nature communications. 2020 Academic Article GET IT
Times cited: 19
Frontiers in cancer immunotherapy-a symposium report. Annals of the New York Academy of Sciences. 2020 Review GET IT
Times cited: 31
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 6
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood cancer discovery. 2020 Academic Article GET IT
Times cited: 106
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood advances. 2020 Academic Article GET IT
Times cited: 148
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers. 2020 Information Resource GET IT
Times cited: 15
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?. Cancer cell. 2020 Comment GET IT
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia. 2020 Academic Article GET IT
Times cited: 33
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone marrow transplantation. 2020 Academic Article GET IT
Times cited: 10
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?. Expert review of hematology. 2020 Review GET IT
Times cited: 9
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells. Cancer immunology research. 2020 Academic Article GET IT
Times cited: 17
Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy. Cancer immunology research. 2020 Academic Article GET IT
Times cited: 17
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. British journal of haematology. 2020 Academic Article GET IT
Times cited: 47
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood advances. 2020 Academic Article GET IT
Times cited: 102
Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells. Clinical nephrology. 2020 Academic Article GET IT
Times cited: 15
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019 Academic Article GET IT
Times cited: 178
Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature reviews. Clinical oncology. 2019 Review GET IT
Times cited: 726
Application of CAR T cells for the treatment of solid tumors. Progress in molecular biology and translational science. 2019 Review GET IT
Times cited: 13
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 56
CAR T-cell therapy: Full speed ahead. Hematological oncology. 2019 Review GET IT
Times cited: 102
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI insight. 2019 Academic Article GET IT
Times cited: 75
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science translational medicine. 2019 Academic Article GET IT
Times cited: 207
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer cell. 2019 Academic Article GET IT
Times cited: 148
CARs of the future. American journal of hematology. 2019 Review GET IT
Times cited: 9
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 2018 Academic Article GET IT
Times cited: 43
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Journal for immunotherapy of cancer. 2018 Review GET IT
Times cited: 163
Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma. Advances in cell and gene therapy. 2018 Academic Article GET IT
Times cited: 140
Tumors evading CARs-the chase is on. Nature medicine. 2018 Comment GET IT
Times cited: 27
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular therapy. Methods & clinical development. 2018 Academic Article GET IT
Times cited: 22
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature biotechnology. 2018 Academic Article GET IT
Times cited: 522
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Academic Article GET IT
Times cited: 184
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 59
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer discovery. 2018 Academic Article GET IT
Times cited: 568
CAR T cells, immunologic and cellular therapies in hematologic malignancies. Best practice & research. Clinical haematology. 2018 Editorial Article GET IT
Times cited: 1
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell reports. 2018 Academic Article GET IT
Times cited: 221
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 74
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Information Resource GET IT
Times cited: 61
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood advances. 2018 Academic Article GET IT
Times cited: 111
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1764
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer cell. 2017 Academic Article GET IT
Times cited: 131
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. Leukemia & lymphoma. 2017 Information Resource GET IT
Times cited: 44
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 Review GET IT
Times cited: 16
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 6
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Scientific reports. 2017 Academic Article GET IT
Times cited: 274
Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacology & therapeutics. 2017 Review GET IT
Times cited: 87
Adoptive T-Cell Therapy for Solid Tumors. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017 Academic Article GET IT
Times cited: 70
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2016 Academic Article GET IT
Times cited: 118
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clinical advances in hematology & oncology : H&O. 2016 Review GET IT
Times cited: 97
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016 Academic Article GET IT
Times cited: 187
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016 Information Resource GET IT
Times cited: 78
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016 Information Resource GET IT
Times cited: 310
Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert review of hematology. 2016 Editorial Article GET IT
Times cited: 39
Toxicity and management in CAR T-cell therapy. Molecular therapy oncolytics. 2016 Information Resource GET IT
Times cited: 642
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochemical Society transactions. 2016 Review GET IT
Times cited: 159
Driving CAR T-cells forward. Nature reviews. Clinical oncology. 2016 Review GET IT
Times cited: 471
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews. Clinical oncology. 2016 Information Resource GET IT
Times cited: 763
Are chimeric antigen receptor T cells ready for prime time?. Clinical advances in hematology & oncology : H&O. 2016 Academic Article GET IT
Times cited: 3
Overcoming Antigen Escape with CAR T-cell Therapy. Cancer discovery. 2015 Comment GET IT
Times cited: 67
Novel immunotherapies in lymphoid malignancies. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 206
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. Journal of translational medicine. 2015 Academic Article GET IT
Times cited: 211
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015 Academic Article GET IT
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Molecular therapy : the journal of the American Society of Gene Therapy. 2015 Academic Article GET IT
Times cited: 190
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. Immunotherapy. 2015 Review GET IT
Times cited: 32
CD19 CAR Therapy for Acute Lymphoblastic Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Information Resource GET IT
Times cited: 32
CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date. Cancer journal (Sudbury, Mass.). 2015 Review GET IT
Times cited: 25
The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene therapy. 2014 Academic Article GET IT
Times cited: 22
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2014 Academic Article GET IT
Times cited: 91
T-cell immunotherapy: looking forward. Molecular therapy : the journal of the American Society of Gene Therapy. 2014 Conference Paper GET IT
Times cited: 56
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2014 Academic Article GET IT
Times cited: 115
Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells. Leukemia research reports. 2014 Academic Article GET IT
Times cited: 15
CD28z CARs and armored CARs. Cancer journal (Sudbury, Mass.). 2014 Information Resource GET IT
Times cited: 80
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 1976
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. International journal of hematology. 2013 Information Resource GET IT
Times cited: 89
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Biochemical and biophysical research communications. 2013 Academic Article GET IT
Times cited: 16
The basic principles of chimeric antigen receptor design. Cancer discovery. 2013 Information Resource GET IT
Times cited: 1021
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?. Hematology/oncology clinics of North America. 2013 Review GET IT
Times cited: 13
Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem cells and development. 2013 Academic Article GET IT
Times cited: 23
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine. 2013 Academic Article GET IT
Times cited: 1642
In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. PloS one. 2012 Academic Article GET IT
Times cited: 38
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012 Academic Article GET IT
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. The journal of gene medicine. 2012 Information Resource GET IT
Times cited: 194
CARs and cancers: questions and answers. Blood. 2012 Comment GET IT
Times cited: 12
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 Academic Article GET IT
Times cited: 537
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology. American Society of Hematology. Education Program. 2012 Information Resource GET IT
Times cited: 72
Cellular therapies in acute lymphoblastic leukemia. Hematology/oncology clinics of North America. 2011 Information Resource GET IT
Times cited: 12
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Academic Article GET IT
Times cited: 1077
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer research. 2011 Academic Article GET IT
Times cited: 82
CARs on track in the clinic. Molecular therapy : the journal of the American Society of Gene Therapy. 2011 Conference Paper GET IT
Times cited: 107
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 127
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood. 2010 Academic Article GET IT
Times cited: 36
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discovery medicine. 2010 Academic Article GET IT
Times cited: 50
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Molecular therapy : the journal of the American Society of Gene Therapy. 2010 Letter GET IT
Times cited: 333
Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discovery medicine. 2010 Review GET IT
Times cited: 20
Cellular therapies in acute lymphoblastic leukemia. Current opinion in molecular therapeutics. 2009 Review GET IT
Times cited: 8
The promise and potential pitfalls of chimeric antigen receptors. Current opinion in immunology. 2009 Information Resource GET IT
Times cited: 390
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nature medicine. 2009 Academic Article GET IT
Times cited: 108
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009 Academic Article GET IT
Times cited: 248
Retroviral transduction of murine primary T lymphocytes. Methods in molecular biology (Clifton, N.J.). 2009 Academic Article GET IT
Times cited: 34
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 63
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 101
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Human gene therapy. 2007 Academic Article GET IT
Times cited: 30
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature medicine. 2007 Academic Article GET IT
Times cited: 208
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 306
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2007 Academic Article GET IT
Times cited: 372
Novel approaches to the immunotherapy of B-cell malignancies: An update. Current hematologic malignancy reports. 2006 Review GET IT
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 140
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer research. 2005 Academic Article GET IT
Times cited: 94
Novel approaches to immunotherapy for B-cell malignancies. Current hematology reports. 2005 Review GET IT
Times cited: 6
Novel approaches to immunotherapy for B-cell malignancies. Current oncology reports. 2004 Review GET IT
Times cited: 4
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Current hematology reports. 2004 Information Resource GET IT
Times cited: 17
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature medicine. 2003 Academic Article GET IT
Times cited: 468
Targeting tumours with genetically enhanced T lymphocytes. Nature reviews. Cancer. 2003 Information Resource GET IT
Times cited: 365
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nature biotechnology. 2002 Academic Article GET IT
Times cited: 592
Fine tangled pili expressed by Haemophilus ducreyi are a novel class of pili. Journal of bacteriology. 1996 Academic Article GET IT
Times cited: 66
Haemophilus ducreyi adheres to human keratinocytes. Microbial pathogenesis. 1994 Academic Article GET IT
Times cited: 25

more ...

less ...

Background

education and training

M.D., Ph.D., State University of New York at Buffalo, School of Medicine and Biomedical Sciences 96
M.A., State University of New York at Buffalo 1994
B.A., Davidson College 1989

VIVO Weill Cornell Medical College

Renier Joseph Brentjens Adjunct Professor of Pharmacology (Courtesy)

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email